Deviating from a guidance [Design Issues]

posted by Pharma_88 – India, 2024-05-21 10:32 (197 d 17:05 ago) – Posting: # 24005
Views: 2,375

Dear Helmut,

Thank you. Yes for For submission study, will definitely initiate CC with FDA. Since this is a pilot study where main objective is to assess the possibility of the single dose administration effect on pharmacokinetic as well as safety. So any possibility to conduct parallel design study? if yes, how it will be designed?

Regards,
Pharma_88

Complete thread:

UA Flag
Activity
 Admin contact
23,332 posts in 4,899 threads, 1,660 registered users;
19 visitors (0 registered, 19 guests [including 8 identified bots]).
Forum time: 02:37 CET (Europe/Vienna)

I don’t write drafts.
I write from the beginning to the end,
and when it’s finished, it’s done.    Clifford Geertz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5